ADVFN Logo

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
Northwest Biotherapeutics Inc (QB)

Northwest Biotherapeutics Inc (QB) (NWBO)

0.5401
-0.00535
(-0.98%)
Closed February 28 04:00PM

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
0.5401
Bid
0.54
Ask
0.547
Volume
2,012,215
0.537 Day's Range 0.5566
0.4001 52 Week Range 1.11
Market Cap
Previous Close
0.54545
Open
0.55
Last Trade
1824
@
0.5401
Last Trade Time
Financial Volume
$ 1,097,653
VWAP
0.545495
Average Volume (3m)
1,759,799
Shares Outstanding
1,153,846,907
Dividend Yield
-
PE Ratio
-1.87
Earnings Per Share (EPS)
-0.09
Revenue
1.68M
Net Profit
-105.03M

About Northwest Biotherapeutics Inc (QB)

Northwest Biotherapeutics, Inc. is a development stage biotechnology company focused on discovering, developing and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer. The Company operates in the United States, the UK, Germany and Canada and is i... Northwest Biotherapeutics, Inc. is a development stage biotechnology company focused on discovering, developing and commercializing immunotherapy products that generate and enhance immune system responses to treat cancer. The Company operates in the United States, the UK, Germany and Canada and is incorporated in Delaware, USA. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Northwest Biotherapeutics Inc (QB) is listed in the Pharmaceutical Preparations sector of the OTCMarkets with ticker NWBO. The last closing price for Northwest Biotherapeutics (QB) was $0.55. Over the last year, Northwest Biotherapeutics (QB) shares have traded in a share price range of $ 0.4001 to $ 1.11.

Northwest Biotherapeutics (QB) currently has 1,153,846,907 shares outstanding. The market capitalization of Northwest Biotherapeutics (QB) is $196.15 million. Northwest Biotherapeutics (QB) has a price to earnings ratio (PE ratio) of -1.87.

NWBO Latest News

Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia

Epazz, Inc. (OTC Pink: EPAZ) ZenaDrone Demonstration to Defense Departments of UAE and Saudi Arabia ? Miami, FL -- (InvestorsHub NewsWire – November 15, 2023) – EmergingGrowth.com, a leadi...

Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000

Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 ?Miami, FL-- (InvestorsHub NewsWire – November 9, 2023) – EmergingGrowth.com, a leading independent small cap media portal...

Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo

Epazz, Inc. (OTC Pink: EPAZ) US Navy Collaboration ZenaDrone 1000 Extreme Weather Demo ? Miami, FL-- (InvestorsHub NewsWire – November 7, 2023) – EmergingGrowth.com, a leading independent ...

Nightfood, Inc. (OTCQB: NGTF) now in Sonesta International Hotels Multiple Brands

Nightfood, Inc. (OTCQB: NGTF) now in Sonesta International Hotels Multiple Brands Nightfood, Inc. (OTCQB: NGTF) just announced that it has teamed up with Sonesta International Hotels Corporation to of...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.0674-11.09465020580.60750.61220.53218614260.55066924CS
4-0.0249-4.407079646020.5650.650.5318690270.56624073CS
12-0.2299-29.85714285710.770.860.5317597990.63552296CS
260.01011.905660377360.531.110.47521769800.73327776CS
52-0.1598-22.8318331190.69991.110.400118790620.66770396CS
156-0.8999-62.49305555561.442.150.386221046070.89998167CS
2600.2911116.9076305220.2492.540.00522874770.84929792CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
VANIVivani Medical Inc
$ 3.6305
(259.46%)
148.8M
VTVTvTv Therapeutics Inc
$ 16.848
(98.21%)
3.06M
ADILAdial Pharmaceuticals Inc
$ 1.60
(83.21%)
111.63M
COCHEnvoy Medical Inc
$ 2.21
(78.23%)
2.82M
BETSBit Brother Ltd
$ 4.18
(67.87%)
60.01M
CRGECharge Enterprises Inc
$ 0.0253
(-57.83%)
97.23M
IASIntergral Ad Science Holding Corporation
$ 10.02
(-41.40%)
15.75M
SMXSMX Security Matters Public Company
$ 0.2183
(-37.61%)
19.86M
INGNInogen Inc
$ 6.29
(-32.66%)
2.83M
PRSTPresto Technologies Inc
$ 0.3975
(-30.26%)
26.78M
MARAMarathon Digital Holdings Inc
$ 31.00
(2.28%)
179.65M
VANIVivani Medical Inc
$ 3.6305
(259.46%)
148.8M
NKLANikola Corporation
$ 0.7684
(1.67%)
121.41M
SOUNSoundHound AI Inc
$ 6.3201
(-7.87%)
118.47M
GOEVCanoo Inc
$ 0.10675
(-6.20%)
114.23M

NWBO Discussion

View Posts
flipper44 flipper44 21 minutes ago
Ok, let’s say you’re right, what do they review in the second assessment (phase ii) besides the responses to the RFI? For the established medicines, the answer is nothing.
👍️ 1
Irishvox Irishvox 1 hour ago
Either way approval is inevitable…
👍️ 1
FeMike FeMike 1 hour ago
“The thing speaks for itself” is a cop out. You may as well admit you can find nowhere that says what you claim. Which it clearly doesn’t.

Even if it did back up your claim which, again, it does not; the guidance you are quoting is for established medicines.
👺 1 💩 1
starric starric 1 hour ago
https://www.pharmaceutical-technology.com/news/biotech-execs-say-ira-is-causing-unintended-effects-for-cancer-drug-development/?cf-view


https://www.nihr.ac.uk/partners-and-industry/industry/uk-research-delivery-spotlights/uk-vaccine-innovation-pathway.htm


https://prescancerpanel.cancer.gov/pdfs/CancerPanelReport.pdf


Good just to see the continued attention and focus on cancer research.
👍️ 1
StonkMaster StonkMaster 1 hour ago
Not to pull hairs, but as I pointed out in my post to you earlier today, DCVAX-L is a NAS not an Established Medicine.
👍️0
flipper44 flipper44 2 hours ago
The thing speaks for itself, but here, below,is the process for established medicines. As you can see, “technical” validity is determined immediately. Or as close to submission as possible, that is not “Phase I” as you claimed in your last quote I gave. Next, the initial assessment is made, which includes “scientific assessment,” (not in phase ii as you claim). In other words, you were wrong. They do make a scientific assessment, and if no issues are raised, it goes straight to a “determination.” If a request for more information is instead issued, the clock goes off for 60 days. The second assessment begins from receipt of the response. If it is a complete response to the RFI a “determination” will be made, just like it would have been in the initial assessment if no issues had arisen.

We are taking significant steps to assess applications for medicines approvals within statutory timeframes. We will always prioritise applications according to public health need.

From 1 March 2024 we will be introducing a process change to ensure applications are complete on initial assessment, or as soon after submission as possible.

Upon receipt of an application MHRA will check documentation provided for technical completeness. If applications are incomplete, they will be refused
Applications which are technically complete will continue on to scientific assessment and where there are issues raised a single request for information (RFI) will be sent out to the applicant (there will no longer be more than one RFI).
Applicants will have 60 calendar days to respond to the RFI.
There will be three outcomes from this point:
If the response is complete the application will be determined
If the response is inadequate on quality, safety or efficacy grounds, then the application will be referred to the Commission for Human Medicines for advice
If no response is received within the timeline of 60 days, then the application will be refused.. https://www.gov.uk/government/publications/mhra-performance-data-for-assessment-of-clinical-trials-and-established-medicines/mhra-performance-data-for-assessment-of-clinical-trials-and-established-medicines#established-medicines
👍️ 3
Chiugray Chiugray 2 hours ago
Same here. IHub is still very slow. I wonder if the X button is new. It is switching back and forth from "X Post" to "Tweet". Maybe it is trying to connect and that is causing a delay. Hope they fix it soon.
👍️0
FeMike FeMike 2 hours ago
Flipper said:

Phase ii is only required if RFI response is required

Show me the link that proves what you said above is true, and you are not making it up.
👺 1 💩 2
flipper44 flipper44 2 hours ago
FEMike said:

Phase I reviews the technical validity of the application.

Phase II reviews the scientific aspect of the application.

Show me the link that proves what you say above is true, and that you are not making it up.
👍️ 2
FeMike FeMike 2 hours ago
Show me one place where it says Phase 2 is cancelled if there is no RFI.

Show me the link.

I can show you plenty of links and quotes that say definitively that the assessment is done in two phases.

You are the one claiming they don’t do phase 2 in some cases. Show me your evidence. Show me the link.
👺 1
flipper44 flipper44 2 hours ago
Show me one place where it says what they do in phase ii besides review the response, if one was required.
👍️ 2
norisknorewards norisknorewards 2 hours ago
22 December 2022 In progress

Good stuff, but certainly not new, am I missing something?
👍️0
FeMike FeMike 2 hours ago
Jesus you are dense.

The onus is not on me to prove Phase 2 does happen. I am not the one that fabricated some bogus claim. The MHRA clearly says everywhere in their literature it is a two phase process.

You all are making up a claim that Phase 2 doesn’t happen if there isn’t an RFI. This is completely fabricated and nowhere is there any evidence that Phase 2 is cancelled if there isn’t an RFI.
👺 1 💩 1
MasterBlastr MasterBlastr 3 hours ago
LOL what about this one - sorry this one won't post but you know what I am getting at, in regards to NWBO.
👍️0
learningcurve2020 learningcurve2020 3 hours ago
Check.

>>Money for their salaries
👍️0
MasterBlastr MasterBlastr 3 hours ago
Total and complete nonsense post.
🎯 1 👍️ 1
flipper44 flipper44 3 hours ago
FEMike said:

“It will also start immediately after P1 if no RFI is required.”

Nope, it doesn’t say that. I’m not putting it past MHRA to be incoherent, but you are making that up.

What it does say is this.

“Phase II assessment will commence on receipt of the applicant’s responses”
👍️ 1
FeMike FeMike 3 hours ago
Never mind, you are right and FeMike is wrong.

Phase ii is only required if RFI response is required, and an RFI is not always issued.

“Phase II assessment will commence on receipt of the applicant’s responses”

Curious, how does what you posted somehow prove that I am wrong? Or prove what you say, “Phase ii is only required if RFI response is required”

Your quote from the article says P2 will start after the applicant responds to the RFI. That is true. It will also start immediately after P1 if no RFI is required. In neither the quote nor the link you provided does anything say or imply that P2 is not necessary if no RFI is given. You, along with Crash and Smitty (Fireman), are making this up.
👺 1
Legend431 Legend431 4 hours ago
Well as a concerned investor you should be raising concerns on the first 2. I have.
👍️0
Chiugray Chiugray 4 hours ago
Same issue. Slow and lots of times error on Ihub. Couldn't post then. Let's see if this goes thru.
👍️0
Horseb4CarT Horseb4CarT 4 hours ago
You FUDsters take note.

Should anyone, especially a young child who should have a lifetime to live and learn so much, have to wait longer or tragically miss out on the chance and hope to live a long time?

Please see the light and be constructive in your humanity! It’s not too late to be a better person.
👍️ 9
Horseb4CarT Horseb4CarT 4 hours ago
Artificially controlled price for now, but the day is coming!
👍️ 6
Horseb4CarT Horseb4CarT 4 hours ago
She should still be in place when the DCVax MAA is approved!

Hopefully with months to spare.
👍️ 1
Foogie88 Foogie88 4 hours ago
You make a good point on your first 2 bullet points, but then you go off the rails like all you fudsters do everyday.
👍️0
biosectinvestor biosectinvestor 4 hours ago
It’s a contingent fee lawsuit… the lawyers they pay for are those getting them through the drug regulatory process, IP lawyers and any regular and normal costs for securities compliance and corporate necessities and compliance.
👍️ 1
Zadie420 Zadie420 5 hours ago
Also NWBO is not paying for lawyers. The lawyers Wii get paid based on the winning the case and collect the $.
👍️ 7 💯 1
Inquirig Inquirig 5 hours ago
10 K out yet?
What a dishonest company. WT Heck?
LOLOLOLOL 🤣
👺 1 💩 4 🤡 1 🦨 1
Survivor2012 Survivor2012 5 hours ago
Yaaasss!! Thanks StonkMaster!!

Redmond, WA (February 26, 2024) – The End Brain Cancer Initiative (EBCI) is advocating for FDA approval of DCVax®-L, a novel treatment for Glioblastoma (GBM) brain tumors, in anticipation of submittal of the application for FDA approval by Northwest Biotherapeutics. The End Brain Cancer Initiative is dedicated to ensuring patients have full access to FDA approved treatments and many different treatment options, such as advanced diagnostics and clinical trials, and now DCVax®-L, which has demonstrated increased survivorship and Quality of Life in approximately 20% of the GBM patients who participated in clinical trials for this treatment.

“The FDA needs to understand that not one treatment is viable for this disease as Glioblastoma (GBM) quickly becomes resistant to all treatment. Therefore, patients need to have multiple and varied treatment options so that when their tumor becomes resistant to a treatment, they are able to quickly pivot to another FDA approved treatment option,” said Dellann Elliott Mydland, End Brain Cancer Initiative (EBCI), CEO & President. “In order to provide brain cancer patients multiple treatment options, increase patient Quality of Life, provide HOPE for this patient community, and encourage additional investment by pharma/biotech companies into GBM research, the FDA needs to approve multiple treatment options for this patient population. Currently, there are a very limited number of treatment options FDA approved for this disease, which limits patient access and decreases survivorship. EBCI and I are working hard to advocate for and expand access to additional treatment options and improve Standard of Care for the brain tumor and brain cancer patient community.”

Call to Action: Team up with the End Brain Cancer Initiative to advocate for FDA approval for DCVax®-L. Raise your voice by sharing your story at app.hatchbuck.com/OnlineForm/936….

DCVax®-L represents a novel form of immunotherapy classified as a dendritic cell vaccine. Developed by Northwest Biotherapeutics, this personalized vaccine is crafted from each patient’s unique dendritic cells, a crucial component aiding the immune system in recognizing and combatting cancer cells. The intricate process involves isolating immune cells from the patient’s blood, exposing them to tumor cells, and enabling dendritic cells to recognize specific markers associated with the patient’s tumor cells. Once re-introduced into the patient’s system, these “educated” dendritic cells recruit and instruct other immune cells, known as T-cells, to travel to the tumor site and attack cancerous cells. Learn more at nwbio.com.

The End Brain Cancer Initiative is a 501(c)3 non-profit patient organization focused on disease education, awareness, outreach and increasing patient access. The End Brain Cancer Initiative, formerly known as the Chris Elliott Fund, is dedicated to ensuring that all patients diagnosed with brain cancer, a brain tumor, or metastatic disease to the brain have equal access to advanced diagnostics, treatments, specialists, and clinical trial participation. We believe that IMMEDIATE ACCESS to these options provides this patient community with the best HOPE for survival and sustained quality of life. We partner with industry, patients, researchers, advocacy groups, medical teams, hospital networks and others to educate patients and their caregivers so they can have empowered conversations with medical teams. Learn more about and support the End Brain Cancer Initiative’s work and mission at EndBrainCancer.org.

Dellann Elliott Mydland
End brain cancer Initiative
+1 425-444-2215
👍️ 4 🚀 1
Survivor2012 Survivor2012 5 hours ago
Yaaasss!! Thanks StonkMaster!!

Redmond, WA (February 26, 2024) – The End Brain Cancer Initiative (EBCI) is advocating for FDA approval of DCVax®-L, a novel treatment for Glioblastoma (GBM) brain tumors, in anticipation of submittal of the application for FDA approval by Northwest Biotherapeutics. The End Brain Cancer Initiative is dedicated to ensuring patients have full access to FDA approved treatments and many different treatment options, such as advanced diagnostics and clinical trials, and now DCVax®-L, which has demonstrated increased survivorship and Quality of Life in approximately 20% of the GBM patients who participated in clinical trials for this treatment.

“The FDA needs to understand that not one treatment is viable for this disease as Glioblastoma (GBM) quickly becomes resistant to all treatment. Therefore, patients need to have multiple and varied treatment options so that when their tumor becomes resistant to a treatment, they are able to quickly pivot to another FDA approved treatment option,” said Dellann Elliott Mydland, End Brain Cancer Initiative (EBCI), CEO & President. “In order to provide brain cancer patients multiple treatment options, increase patient Quality of Life, provide HOPE for this patient community, and encourage additional investment by pharma/biotech companies into GBM research, the FDA needs to approve multiple treatment options for this patient population. Currently, there are a very limited number of treatment options FDA approved for this disease, which limits patient access and decreases survivorship. EBCI and I are working hard to advocate for and expand access to additional treatment options and improve Standard of Care for the brain tumor and brain cancer patient community.”

Call to Action: Team up with the End Brain Cancer Initiative to advocate for FDA approval for DCVax®-L. Raise your voice by sharing your story at app.hatchbuck.com/OnlineForm/936….

DCVax®-L represents a novel form of immunotherapy classified as a dendritic cell vaccine. Developed by Northwest Biotherapeutics, this personalized vaccine is crafted from each patient’s unique dendritic cells, a crucial component aiding the immune system in recognizing and combatting cancer cells. The intricate process involves isolating immune cells from the patient’s blood, exposing them to tumor cells, and enabling dendritic cells to recognize specific markers associated with the patient’s tumor cells. Once re-introduced into the patient’s system, these “educated” dendritic cells recruit and instruct other immune cells, known as T-cells, to travel to the tumor site and attack cancerous cells. Learn more at nwbio.com.

The End Brain Cancer Initiative is a 501(c)3 non-profit patient organization focused on disease education, awareness, outreach and increasing patient access. The End Brain Cancer Initiative, formerly known as the Chris Elliott Fund, is dedicated to ensuring that all patients diagnosed with brain cancer, a brain tumor, or metastatic disease to the brain have equal access to advanced diagnostics, treatments, specialists, and clinical trial participation. We believe that IMMEDIATE ACCESS to these options provides this patient community with the best HOPE for survival and sustained quality of life. We partner with industry, patients, researchers, advocacy groups, medical teams, hospital networks and others to educate patients and their caregivers so they can have empowered conversations with medical teams. Learn more about and support the End Brain Cancer Initiative’s work and mission at EndBrainCancer.org.

Dellann Elliott Mydland
End brain cancer Initiative
🍻 2 👍️ 6 😁 1
GrannPiano GrannPiano 5 hours ago
The trial partner will bring the cash. There are some good forums where could learn about investing and biotech and how funding works. Might be fun for you!
🎯 1 👍️ 5 💥 3 🤡 2
insidernews insidernews 5 hours ago
They don't have the cash to run trials right now. They need the cash for lawyers in the spoofing case. Money For repay loans. Money for their salaries
👍️0
learningcurve2020 learningcurve2020 5 hours ago
It's a toss up.
👿 1 💩 1
Inquirig Inquirig 5 hours ago
Coming from a dolt who owns this scam stock, that is my greatest compliment.

THANKS
🐀 1 👺 1 💩 2 🤡 1
insidernews insidernews 6 hours ago
You're a idiot. In my humblest opinion
🏁 1 👍️ 4 💚 1 💥 2 💯 1 ❤️ 1
flipper44 flipper44 6 hours ago
This website is still slow, just not as slow as this morning.
👍️0
Inquirig Inquirig 6 hours ago
Maybe years ago, but now LP has Advent to fall back on

She can shut it down and have Advent buy the relevant patents for $10 or $20 Million and walk away richer than ever.. While the NWBO bag holders get screwed .... again

Just my opinion
🐀 1 👺 1 💩 2 🤡 1
Inquirig Inquirig 6 hours ago
Where's the 10 K ?
Where is the ASM?
Where is the update on the app submission?
How many shares of dilution?
What is the Advent royalty split?
Who is dumb enough to buy this stock?

All posts are my opinion and for debate purposes only.. ;)
👺 1 💩 3 🤡 1
learningcurve2020 learningcurve2020 6 hours ago
They've maybe kept their distance from that fate. My guess is a reverse merge to make everything go away.
👿 1 💩 2
Inquirig Inquirig 6 hours ago
I think Bankruptcy is next for NWBO... Total scam.

Just my very humblest of opinions
🐀 1 👺 1 💩 4 🤡 1
learningcurve2020 learningcurve2020 6 hours ago
KIPK came from the "Abby Normal" jar.
👿 1 💩 1
Arby2000 Arby2000 6 hours ago
humble opinion

Nope. Never saw that laudable trait in your posts.
👍️ 1 🤣 1
georgebailey georgebailey 6 hours ago
Nope nwbo will never equal your value Inquirig
Not an opinion.
👍️0
georgebailey georgebailey 6 hours ago
Nope nwbo will never equal your value Inquirig
Not an opinion.
👍️0
georgebailey georgebailey 6 hours ago
Nope nwbo will never equal your value Inquirig
Not an opinion.
👍️ 1
Inquirig Inquirig 6 hours ago
NWBO is going to $ ZERO

In my very humble opinion...
👍️ 1 👺 1 💩 3 💯 1 🖕 1 😂 1 🤡 1
CrashOverride CrashOverride 6 hours ago
I agree the trials should begin as soon as possible.
👍️0
Zadie420 Zadie420 6 hours ago
I agree. You don’t wanna wait for Eden approval to run the trials. You stick with known facts. You can not bring unknown factor into the equation.
👍️ 1
StonkMaster StonkMaster 6 hours ago
Yes sir!
👍️ 4
Inquirig Inquirig 6 hours ago
MORON
👺 1 💩 3 🖕 1
Red_Right_Hand Red_Right_Hand 6 hours ago
https://t.co/0LTLYKpxbQ $nwbo @alphavestcap https://t.co/YkfjOTGgiVhttps://t.co/OQU4XTi7Eghttps://t.co/ugXAyPPUvR
"I’m only speculating here, but it would be a great surprise to hear something from NICE next week and then soon after MAA approval by end of March to middle… pic.twitter.com/s00LOA7hG4— alphavestcapital.com (@alphavestcap) February 28, 2024
🍎 1 👍️ 6 💪 4 🔑 1

Your Recent History

Delayed Upgrade Clock

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

Support: 1-888-992-3836 | help@advfn.com